Please use this identifier to cite or link to this item:
Title: Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis
Authors: BAUTISTA-MOLANO, WilsonFERNANDEZ-AVILA, Daniel G.BRANCE, Maria LorenaPEDRETTI, Maria Gabriela AvilaBURGOS-VARGAS, RubenCORBACHO, InesCOSENTINO, Vanesa LauraCOTO, Jose Francisco DiazHO, Enrique GiraldoRESENDE, Gustavo GomesGUTIERREZ, Luis ArturoGUTIERREZ, MarwinVODNIZZA, Sebastian Eduardo IbanezJAUREGUI, EdwinOCAMPO, VanessaRIVERO, Daniel Ruben PalleiroPALOMINOS, Penelope EstherTENA, Cesar PachecoQUICENO, Guillermo AndresSALDARRIAGA-RIVERA, Lina MariaSOMMERFLECK, Fernando AndresSARIEGO, Annelise GoeckeBARREZUETA, Claudia VeraESPINOZA, Luis Enrique VegaHINOJOSA, Oscar VegaCITERA, GustavoLOZADA, CarlosSAMPAIO-BARROS, Percival D.SCHNEEBERGER, EmilceSORIANO, Enrique R.
Citation: NATURE REVIEWS RHEUMATOLOGY, v.19, n.11, p.724-737, 2023
Abstract: Axial spondyloarthritis (axSpA) comprises a spectrum of chronic inflammatory manifestations affecting the axial skeleton and represents a challenge for diagnosis and treatment. Our objective was to generate a set of evidence-based recommendations for the management of axSpA for physicians, health professionals, rheumatologists and policy decision makers in Pan American League of Associations for Rheumatology (PANLAR) countries. Grading of Recommendations, Assessment, Development and Evaluation-ADOLOPMENT methodology was used to adapt existing recommendations after performing an independent systematic search and synthesis of the literature to update the evidence. A working group consisting of rheumatologists, epidemiologists and patient representatives from countries within the Americas prioritized 13 topics relevant to the context of these countries for the management of axSpA. This Evidence-Based Guideline article reports 13 recommendations addressing therapeutic targets, the use of NSAIDs and glucocorticoids, treatment with DMARDs (including conventional synthetic, biologic and targeted synthetic DMARDs), therapeutic failure, optimization of the use of biologic DMARDs, the use of drugs for extra-musculoskeletal manifestations of axSpA, non-pharmacological interventions and the follow-up of patients with axSpA.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.3 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.